Published in Liver Transpl Surg on November 01, 1997
Hepatopulmonary Syndrome and Portopulmonary Hypertension. Curr Treat Options Cardiovasc Med (2002) 0.84
Management of portopulmonary hypertension: new perspectives. World J Gastroenterol (2013) 0.76
Hepatopulmonary Syndrome and Portopulmonary Hypertension. Curr Treat Options Gastroenterol (2001) 0.75
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Some Aspects of Nutritional Variation of the Gonococcus. J Bacteriol (1943) 8.22
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55
Charge-induced reversible strain in a metal. Science (2003) 2.55
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Identification of oda6 as a Chlamydomonas dynein mutant by rescue with the wild-type gene. J Cell Biol (1991) 2.42
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Impairment of motor coordination, Purkinje cell synapse formation, and cerebellar long-term depression in GluR delta 2 mutant mice. Cell (1995) 2.25
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science (1999) 2.19
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med (1998) 2.14
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Control of the development of iron-efficiency reactions in potato as a response to iron deficiency is located in the roots. Plant Physiol (1987) 1.87
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82
The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care (2000) 1.81
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78
Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72
Transplantation. JAMA (1990) 1.71
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm. Proc Natl Acad Sci U S A (2000) 1.67
Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med (1995) 1.59
High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med (1994) 1.59
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59
The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth (1992) 1.57
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
Management and long-term follow-up of hepatic cysts. Am J Surg (2001) 1.57
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56
Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone. Osteoporos Int (2006) 1.56
Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol (2000) 1.56
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg (1999) 1.55
Piggyback orthotopic intestinal transplantation. Surg Gynecol Obstet (1993) 1.55
Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene (2009) 1.54
Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53
Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49